Literature DB >> 11934726

Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids.

G Umberto Meduri1, Elizabeth A Tolley, George P Chrousos, Frankie Stentz.   

Abstract

Nuclear factor-kappaB (NF-kappaB) and glucocorticoid receptor-alpha (GR-alpha) have diametrically opposed functions in regulating inflammation. We investigated whether unresolving acute respiratory distress syndrome (ARDS) is associated with systemic inflammation- induced glucocorticoid resistance and whether prolonged methylprednisolone administration accelerates the suppression of systemic inflammatory indices and normalizes the sensitivity of the immune system to glucocorticoids. Patients enrolled into a randomized trial evaluating prolonged methylprednisolone administration in unresolving ARDS had serial plasma samples collected before and after randomization. In the plasma, we measured the concentrations of tumor necrosis factor-alpha (TNF-alpha), interleukins (IL) IL-1beta and IL-6, adrenocorticotropic hormone (ACTH), and cortisol. The ability of patient plasma to influence the NF-kappaB and GR-signal transduction systems of normal peripheral blood leukocytes (PBL) was examined. Patients treated with methylprednisolone had progressive and sustained reductions of TNF-alpha, IL-1beta, IL-6, ACTH, and cortisol concentrations over time. Normal PBL exposed to plasma samples collected during methylprednisolone exhibited significant progressive increases in all aspects of GR-mediated activity and significant reductions in NF-kappaB DNA-binding and transcription of TNF-alpha and IL-1beta. These findings provide support for the presence of endogenous glucocorticoid inadequacy in the control of inflammation and systemic inflammation-induced peripheral glucocorticoid resistance in ARDS. Prolonged methylprednisolone administration accelerated the resolution of both systemic inflammation and peripheral acquired glucocorticoid resistance in ARDS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934726     DOI: 10.1164/ajrccm.165.7.2106014

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  66 in total

Review 1.  [Corticosteroid administration for acute respiratory distress syndrome : therapeutic option?].

Authors:  P Möhnle; J Briegel
Journal:  Anaesthesist       Date:  2012-04       Impact factor: 1.041

Review 2.  Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature.

Authors:  G Umberto Meduri; Lisa Bridges; Mei-Chiung Shih; Paul E Marik; Reed A C Siemieniuk; Mehmet Kocak
Journal:  Intensive Care Med       Date:  2015-10-27       Impact factor: 17.440

3.  Steroids are part of rescue therapy in ARDS patients with refractory hypoxemia: yes.

Authors:  Thomas Bein; Josef Briegel; Djillali Annane
Journal:  Intensive Care Med       Date:  2016-02-16       Impact factor: 17.440

4.  Inhibition of endogenous glucocorticoid synthesis aggravates lung injury triggered by septic shock in rats.

Authors:  Erika K Incerpi; Luiz M Oliveira; Elisângela M Pereira; Roseli Soncini
Journal:  Int J Exp Pathol       Date:  2015-02-09       Impact factor: 1.925

5.  Diffuse alveolar damage in nonresolving ARDS provides support for prolonged glucocorticoid treatment.

Authors:  Gianfranco Umberto Meduri
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

Review 6.  Corticosteroid therapy in acute respiratory distress syndrome.

Authors:  François Lamontagne; Roy Brower; Maureen Meade
Journal:  CMAJ       Date:  2012-11-12       Impact factor: 8.262

Review 7.  Psychosocial stress and cardiovascular diseases.

Authors:  S Vale
Journal:  Postgrad Med J       Date:  2005-07       Impact factor: 2.401

Review 8.  Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM).

Authors:  Djillali Annane; Stephen M Pastores; Wiebke Arlt; Robert A Balk; Albertus Beishuizen; Josef Briegel; Joseph Carcillo; Mirjam Christ-Crain; Mark S Cooper; Paul E Marik; Gianfranco Umberto Meduri; Keith M Olsen; Bram Rochwerg; Sophia C Rodgers; James A Russell; Greet Van den Berghe
Journal:  Intensive Care Med       Date:  2017-09-21       Impact factor: 17.440

Review 9.  [Corticosteroid insufficiency in the critically ill. Pathomechanisms and recommendations for diagnosis and treatment].

Authors:  J Briegel; M Vogeser; D Keh; P Marik
Journal:  Anaesthesist       Date:  2009-02       Impact factor: 1.041

Review 10.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.